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comes. It is a 60-item questionnaire that contains the SF-
36 plus Pain Symptom, Functional Limitations, Perceived
Family/Social Disability, Real Family/Social Disability
and Formal Work Disability scales. RESULTS: Five 
thousand two hundred thirty-ﬁve TOPS instruments were
completed in 3,637 PMC patients from 1997 to 2002.
4,511 are <65 years, 392 are 65–74, and 332 are 75+.
Psychometric performance, evaluated with Cronbach’s
alpha index of internal consistency reliability, of the SF-
36/TOPS scales in this elderly population was consist-
ent with published validation standards. SF-36 Physical
Component Summary (PCS), Mental Component
Summary (MCS) and the TOPS Total Pain Experience
scales (TPE, a composite of 7 TOPS scales), for chronic
pain patients <65, 65–74 and >75 are: PCS (29.6, 27.9,
26.4), MCS (39.7, 42.2, 42.9), and TPE (60, 58.8, 61.1).
The PCS and MCS were signiﬁcantly different (p < 0.05)
when patients <65 were compared with older patients.
Top 5 ICD9 diagnoses in each age group accounted for
52–60% of diagnoses reported, with myalgia and myosi-
tis (729.1) and lumbago (724.2) being ﬁrst and second
ranked in each age group. Neuralgia, neuritis and radi-
culitis incidence was in the top ﬁve reported ICD9 diag-
noses for both older age groups, while herpes zoster
complications was reported only in the 75+ age group.
Inﬂuence of gender and work disability were also ana-
lyzed and will be presented. CONCLUSIONS: Older
chronic pain patients have a higher PCS, lower MCS,
similar TPE, and different diagnoses, as compared with
younger patients.
URINARY & KIDNEY DISEASES/DISORDERS—
Clinical Outcomes/Healthcare Policy
PRK1
COMPARISON OF DIRECT HEALTH-CARE COST,
HOSPITAL UTILIZATION AND MEDICATION
PERSISTENCE BETWEEN EXTENDED RELEASE
FORMS (ER) OF TOLTERODINE AND
OXYBUTYNIN IN OVERACTIVE
BLADDER/URINARY INCONTINENCE PATIENTS
Yu YF1,Yu AP2,Ahn J1, Nichol MB1
1University of Southern California, Los Angeles, CA, USA;
2USC School of Pharmacy, Los Angeles, CA, USA
OBJECTIVES: Tolterodine-ER is a newly-released 
medication for Overactive Bladder/Urinary Incontinence
(OAB/UI). This retrospective study investigated the dif-
ference in direct health-care cost, hospital utilization, and
medication persistence between OAB/UI patients initiated
with tolterodine-ER or oxybutynin-ER. METHODS:
Newly started adult patients (age > = 18) on either
tolterodine-ER or oxybutynin-ER from October 2001 to
May 2002 with 1-year washout period, were included
and followed up until the end of study period or disen-
rollment. The log-transformed direct healthcare cost
(excluding OAB-related pharmacy cost per member per
month) was analyzed by ANCOVA. Control variables
include demographics, previous hospital utilizations,
medication pattern, prior OAB diagnosis and comorbidi-
ties. A Cox Proportional Hazard model was applied to
examine the effect of different initial treatments on per-
sistence described by time to switch and time to discon-
tinuation. Logistic regression was used to assess the risk
of hospitalization associated with the ﬁrst prescription.
RESULTS: Of 1811 patients, 1021 patients started 
with tolterodine-ER, and 790 with oxybutynin-ER. The
average follow-up period for both groups was ﬁve
months. No signiﬁcant difference was found in the 
converted adjusted costs PMPM between tolterodine-ER
group (US$602) and oxybutynin-ER group (US$648)
with P = 0.324. Two groups had similar physician
encounter frequency (one visit PMPM) and emergency
room visit rate (2%), but tolterodine-ER initiated patients
were less frequently hospitalized (9.11% vs. 13.16%, P =
0.006). A higher proportion of oxybutynin-ER initiated
patients discontinued (56.6% vs. 52.5 %, P = 0.08) and
switched (7.85% vs. 7.54%, P = 0.808). The type of
initial therapy did not signiﬁcantly affect time to discon-
tinuation or time to switch, but initiating tolterodine-ER
could reduce the probability of hospitalization by 32%
(OR: 0.677, P = 0.037). CONCLUSIONS: Initial drug
selection did not signiﬁcantly change direct healthcare
cost, medical utilization, and medication persistence in
OAB/UI patients. However, patients initiating with oxy-
butynin-ER were exposed to a higher risk of hospitaliza-
tion than those initiating with tolterodine-ER.
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OBJECTIVES: Kidney failure affects approximately
300,000 people within the United States who require dial-
ysis therapy. Health care for affected patients is mainly
provided through the Medicare program. The literature
has shown that kidney failure has a signiﬁcant emotional,
psychological and ﬁnancial impact on affected patients
and society. There could be several factors that determine
patient utilization costs. Our objective is to identify the
demographic, clinical, and treatment facility factors that
signiﬁcantly explain the costs associated with kidney
failure treatment. METHODS: The study sample con-
sisted of 47,285 Medicare eligible dialysis patients. Data
were extracted for a 1-year period (1999). Predictor vari-
ables included patient demographics, treatment facility,
and several other kidney related laboratory test values
(such as creatinine clearance rates, co-morbidities, BUN,
and hematocrit at baseline). Outcome variables included
the dialysis treatment costs for epoetin and iron injec-
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tions. Two separate linear regression models were created
and analyzed. RESULTS: The chosen predictor variables
identiﬁed 9%, 4%, and 5% of the variance in treatment
costs for epoetin and iron injections, respectively. Signif-
icant predictors (p < 0.05) common to both models in-
cluded demographics, treatment facility, albumin levels,
body mass index, presence of heart conditions, end stage
renal disease (ESRD) for 2–3 year, ESRD for greater than
3 years, hypertension, BUN, and skilled nursing facility
wage index. Females, whites, increased body mass index,
and treatment at skilled nursing facilities were associated
with higher treatment costs. However, the relationship of
certain laboratory tests showed opposing relationships
with the outcome variable. CONCLUSIONS: Through
this study we found further evidence to reinforce ﬁndings
from the literature that dialysis related treatment costs are
inﬂuenced by a wide variety of variables. However, the
relationships vary with respect to the treatment chosen.
Future research should focus on employing additional
factors, which may help increase the explanation of dial-
ysis related treatment costs.
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Several published studies have reported on the estimated
costs associated with overactive bladder (OAB)—a con-
dition characterized by the symptom of urinary urgency,
not necessarily accompanied by incontinence, and often
associated with urinary frequency and nocturia. Although
OAB has been ranked among the 10 most common
chronic conditions in the United States, no known pub-
lished research has rigorously analyzed a key cost com-
ponent—the number of medical visits associated with 
this condition. OBJECTIVES: This study was designed to
explore US national data sets to recover component esti-
mates of resource use (c.f., ofﬁce visits, emergency visits,
hospitalizations) associated with symptoms of OAB.
METHODS: We examined US national databases to esti-
mate the number of annual OAB-associated medical visits
among patients at least 18 years of age. Three datasets
were used and included the National Ambulatory
Medical Care Survey (NAMCS), National Hospital
Ambulatory Medical Care Survey (NHAMCS), and the
National Hospital Discharge Survey (NHDS). Design
based statistical analyses were used to fully account for
the complex survey designs. Diagnostic codes identifying
patients with OAB symptomatology included ICD-9-CM
788.31, 788.41, and 788.33. RESULTS: During year
2000, there were an estimated 1.4 million (95% CI:
1.1–1.8 million) US ambulatory visits, with symptoms
characteristic of OAB, made to nonfederal ofﬁce-based
physicians. Even accounting for ER and outpatient
department visits as well as nonfederal short-stay hospi-
tal discharges, the estimated number of medical visits
with OAB-associated symptoms was less than 1.5 million.
CONCLUSIONS: Based on data derived from the
NOBLE program, a telephone and postal survey designed
to evaluate the prevalence of OAB, there are as many as
34 million adult Americans with OAB. Thus, conserva-
tively assuming one annual medical encounter per patient,
as few as 4% of these individuals sought medical treat-
ment during the year 2000. These statistics, therefore,
suggest a large unmet medical need.
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OBJECTIVE: Renal insufﬁciency, a chronic condition,
can adversely affect workforce productivity and increase
the economic burden on employers. This analysis quan-
tiﬁes the incremental direct (medical, drugs) and indirect
(absenteeism, disability) costs of NDRI from an
employer’s perspective. METHODS: Based on eligibility,
medical, pharmacy and disability claims data from 7 large
US employers covering January 1, 1998 through June 30,
2001, 1278 NDRI patients with at least 2 claims carry-
ing a renal insufﬁciency (RI) ICD-9 diagnosis code less
than 90 days apart were identiﬁed. These patients were
observed from the month of the ﬁrst RI diagnosis to the
month preceding the ﬁrst renal dialysis claim. A 10%
random sample of 154,171 individuals without NDRI
was selected as controls. Employer costs were measured
based on direct medical costs and employee productivity
loss. A tobit regression, which corrects for non-normality
of costs, included controls for age, gender, health plan,
location, diabetes, heart failure, any transplantation, and
liver cirrhosis. RESULTS: The unadjusted ratio of mean
direct and indirect costs for NDRI patients compared to
non-NDRI patients was 17.73 :1 ($1779.90 vs. $100.37
per patient-month, p < .01) and 5.91 :1 ($583.16 vs.
$98.74 per patient-month, p < .01), respectively. After
controlling for confounding factors, the ratios were 
5.50 :1 (95% CI: 5.47–5.53) for direct costs, and 2.10 :1
(95% CI: 2.02–2.17) for indirect costs. Regressions on
sub-categories yielded costs ratios for inpatient care, out-
patient care, prescription drugs, absenteeism, and dis-
ability (short and long-term) of 5.29 :1 (95% CI:
5.23–5.35), 4.05 :1 (95% CI: 4.01–4.08), 3.57 :1 (95%
CI: 3.55–3.59), 1.96 :1 (95% CI: 1.80–2.12), and 1.79 :
1 (95% CI: 1.75–1.83), respectively. CONCLUSION:
Both the unadjusted and adjusted cost ratios for NDRI
